印度征收三种抗癌药品税,使病人更能负担得起这些药品。 India slashes taxes on three anticancer drugs to make them more affordable for patients.

印度政府将三种抗癌症药物——Trastuzumab Deruxtecan、Osimertinib和Durvalumab——的最高零售价格降低到零,将GST税率从12%降至5%。 The Indian government has reduced the Maximum Retail Price (MRP) of three anticancer drugs—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—by cutting customs duties to zero and reducing GST rates from 12% to 5%. 此举旨在降低癌症患者的费用,改善患者获得这些药物的机会。 This move aims to lower costs for cancer patients and improve access to these medications. 制造商遵守了该指令并相应更新其价格。 Manufacturers have complied with the directive and updated their prices accordingly.